BioSpace News Archive

Transparency Market Research has published a new report titled, ‘Diabetes Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global genetic testing services market size would reach US$ 64,131.4 million by 2025 and is expected to grow at a healthy CAGR of 7.6% between 2020 and 2025.

The term biofilms is defined as a collection of microorganisms which grow on different surfaces. Microorganisms that form biofilms include bacteria, fungi, and protists.

OSE Immunotherapeutics announces the positive analysis of the first data of CoVepiT, its prophylactic vaccine candidate against COVID-19, in particular positive interim immunological results on T cell response obtained in 100% of the treated population, with in parallel a resolution of local indurations observed during vaccination.

Nordic Nanovector ASA, a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, will host an R&D day starting at 14:00 CET/ 13:00 GMT/ 08:00 ET.

As of , 30 November 2021, the total number of shares and votes in XVIVO Perfusion AB is 29,498,666.

Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, announced the appointment of Dr Rory Curtis as Vice President US Commercial Operations.

Mainz Biomed N.V. announced the Company has engaged Precision for Medicine, a leading global Clinical Research Organization, to provide U.S. regulatory and reimbursement advisory support for ColoAlert, Mainz’s highly efficacious and easy-to-use diagnostic test for colorectal cancer.

COVID-19 of mild to moderate severity in pregnant women appears to have no effect on the brain of the developing fetus, according to a study being presented at the annual meeting of the Radiological Society of North America.

Isarna Therapeutics announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase 2a clinical study to evaluate Isarna’s lead candidate ISTH0036 in patients with wet age-related macular degeneration and diabetic macular edema.